- At least 23,000 die from antibiotic-resistant infections each year, CDC finds
- Study from NCPA sheds new light on med synchronization programs
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- Walgreens partners with United Nations Foundation's Shot@Life campaign
- Chickenpox vaccine does not appear to increase incidence of shingles, study finds
HAWTHORNE, N.Y. — The Food and Drug Administration has approved a topical treatment for skin conditions made by Israeli generic drug maker Taro Pharmaceutical Industries.
Taro announced Monday the approval of imiquimod cream in the 5% strength. The drug is used to treat actinic keratosis and external genital warts, and is a generic version of Graceway Pharmaceuticals’ Aldara.
Imiquimod cream has annual sales of around $340 million in the United States, according to Taro.